ContraFect Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for ContraFect.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	23.5%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	09 Nov 2023

Recent future growth updates

Recent updates

Are Institutions Heavily Invested In ContraFect Corporation's (NASDAQ:CFRX) Shares?

Mar 09

Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?

Jan 15

What Type Of Shareholders Make Up ContraFect Corporation's (NASDAQ:CFRX) Share Registry?

Nov 24

Contrafect EPS beats by $0.16

Nov 13

Earnings and Revenue Growth Forecasts

OTCPK:CFRX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	N/A	N/A	N/A	N/A	1
12/31/2024	N/A	N/A	N/A	N/A	1
12/31/2023	N/A	N/A	N/A	N/A	1
9/30/2023	N/A	-24	-36	-36	N/A
6/30/2023	N/A	-36	-37	-37	N/A
3/31/2023	N/A	-46	-43	-43	N/A
12/31/2022	N/A	-65	-46	-46	N/A
9/30/2022	N/A	-60	-45	-45	N/A
6/30/2022	N/A	-48	-46	-46	N/A
3/31/2022	N/A	-35	-44	-44	N/A
12/31/2021	N/A	-20	-41	-41	N/A
9/30/2021	N/A	-22	-40	-40	N/A
6/30/2021	N/A	-14	-37	-37	N/A
3/31/2021	N/A	-26	-35	-35	N/A
12/31/2020	N/A	-28	-33	-33	N/A
9/30/2020	N/A	-32	-33	-33	N/A
6/30/2020	N/A	-41	-29	-29	N/A
3/31/2020	N/A	-32	-28	-28	N/A
12/31/2019	N/A	-13	-27	-27	N/A
9/30/2019	N/A	3	-27	-27	N/A
6/30/2019	N/A	4	-29	-29	N/A
3/31/2019	N/A	-7	-27	-27	N/A
12/31/2018	N/A	-38	-26	-26	N/A
9/30/2018	N/A	-48	-25	-25	N/A
6/30/2018	N/A	-46	-25	-25	N/A
3/31/2018	N/A	-28	-25	-25	N/A
12/31/2017	N/A	-16	-25	-25	N/A
9/30/2017	N/A	-10	-27	-27	N/A
6/30/2017	N/A	-19	N/A	-29	N/A
3/31/2017	N/A	-26	N/A	-29	N/A
12/31/2016	N/A	-29	N/A	-29	N/A
9/30/2016	N/A	-37	N/A	-27	N/A
6/30/2016	N/A	-32	N/A	-25	N/A
3/31/2016	N/A	-29	N/A	-24	N/A
12/31/2015	N/A	-25	N/A	-22	N/A
9/30/2015	N/A	-22	N/A	-20	N/A
6/30/2015	N/A	-33	N/A	-20	N/A
3/31/2015	N/A	-34	N/A	-17	N/A
12/31/2014	N/A	-35	N/A	-15	N/A
9/30/2014	N/A	-41	N/A	-14	N/A
6/30/2014	N/A	-29	N/A	-12	N/A
3/31/2014	N/A	-24	N/A	-13	N/A
12/31/2013	N/A	-24	N/A	-14	N/A
9/30/2013	N/A	-19	N/A	-15	N/A
6/30/2013	N/A	-20	N/A	-16	N/A
3/31/2013	N/A	-20	N/A	-17	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if CFRX's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if CFRX's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if CFRX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if CFRX's revenue is forecast to grow faster than the US market.

High Growth Revenue: CFRX is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CFRX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

ContraFect Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased to US$2.00

No longer forecast to breakeven

Price target decreased to US$13.00

Price target decreased to US$13.00

Price target decreased to US$13.00

Forecast to breakeven in 2024

Recent updates

ContraFect Corporation Filed for Bankruptcy

ContraFect Corporation Announces Chief Executive Officer Changes

ContraFect Receives Determination Letter from the Nasdaq Hearings Advisor to Delist its Common Stock from the Nasdaq Capital Market

ContraFect Receives Non Compliance Notice from Nasdaq

Nasdaq Determines to Delist ContraFect's Common Stock from The Nasdaq Capital Market Due to Non-Compliance with Minimum Stockholders' Equity Requirement

ContraFect Corporation Presents Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company's Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-Neg Pathogens

ContraFect Announces Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Nasdaq Determines to Deny ContraFect's Request for Continued Listing on the Nasdaq Capital Market

ContraFect Corporation Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase

ContraFect Corporation Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections

Price target decreased to US$2.00

ContraFect Receives Non-Compliance Letter from Nasdaq

Contrafect Corporation Announces Resignation of Cara Cassino as Chief Medical Officer and Executive Vice President of Research and Development

Contrafect GAAP EPS of -$0.46 misses by $0.13

No longer forecast to breakeven

Contrafect Announces Independent Dsmb Recommends Exebacase Phase 3 Disrupt Study Be Stopped for Futility Following Interim Analysis

ContraFect sinks ~76% as data safety board recommends ending co's DISRUPT trial

ContraFect (NASDAQ:CFRX) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$13.00

ContraFect Corporation, Annual General Meeting, May 17, 2022

Price target decreased to US$13.00

Price target decreased to US$13.00

Forecast to breakeven in 2024

Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?

ContraFect: Non-Antibiotic Alternative That Could Disrupt The Antibiotic Market

We're Keeping An Eye On ContraFect's (NASDAQ:CFRX) Cash Burn Rate

ContraFect Corporation(NasdaqCM:CFRX) dropped from Russell 3000E Growth Index

Forecast to breakeven in 2024

Price target decreased to US$15.90

Is ContraFect (NASDAQ:CFRX) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

ContraFect Corporation Announces BARDA Contract Award for Up to $86.8 Million and Provides Business Outlook

Are Institutions Heavily Invested In ContraFect Corporation's (NASDAQ:CFRX) Shares?

New 90-day low: US$4.81

ContraFect Corporation Appoints Jane F. Barlow to its Board of Directors

New 90-day low: US$4.96

Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?

New 90-day low: US$5.09

New 90-day high: US$5.87

What Type Of Shareholders Make Up ContraFect Corporation's (NASDAQ:CFRX) Share Registry?

Contrafect EPS beats by $0.16

Analysts update estimates

ContraFect Corporation announced that it has received $3 million in funding from Pfizer Inc.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies